Ann: September 2021 Quarterly Activities Report and Appendix 4C, page-6

I disagree on the cash burn; NOX runs on the smell of an oily rag, relative to it's outputs and contributions.

Otherwise, your points are fair @GoldStar112, which is why we won't see much SP movement on the back of this quarterly, I guess.

But... the science is solid. There is plenty of reading between the lines to be done, and there are lots of dots starting to be joined, which makes this the biotech bet of the century. For my money anyway.

I mean, the information on the compassionate use programme alone is incredible.